Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
R. Somers
Sign up to set email alerts
76
Publications
1,351
Citation Statements Received
52
Citation Statements Given
How they've been cited
3,654
64
1,270
17
How they cite others
1,235
4
48
0
Affiliations
The Netherlands Cancer Institute
,
Nederlands Meetinstituut
Publications
Order By: Most citations
Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood
van Leeuwen
1
,
Klokman
2
,
Veer
3
et al.
2000
JCO
Abstract
Show
417
12
235
2
Get access via publisher
Add to collection
Cite
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen
1
,
Klokman
2
,
Hagenbeek
3
et al.
1994
JCO
Abstract
Show
431
9
209
4
Get access via publisher
Add to collection
Cite
Second cancer risk following testicular cancer: a follow-up study of 1,909 patients.
van Leeuwen
1
,
Stiggelbout
2
,
van den Belt‐Dusebout
3
et al.
1993
JCO
Abstract
Show
254
13
121
1
Get access via publisher
Add to collection
Cite
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.
Guglielmi
1
,
Gómez
2
,
Philip
3
et al.
1998
JCO
Abstract
Show
149
7
89
2
Get access via publisher
Add to collection
Cite
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
van Leeuwen
1
,
Chorus
2
,
van den Belt‐Dusebout
3
et al.
1994
JCO
Abstract
Show
184
4
64
1
Get access via publisher
Add to collection
Cite
Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas
Bramwell
1
,
Mouridsen
2
,
Santoro
3
et al.
1987
European Journal of Cancer and Clinical Oncology
237
2
58
0
Get access via publisher
Add to collection
Cite
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group
Mouridsen
1
,
Bastholt
2
,
Somers
3
et al.
1987
European Journal of Cancer and Clinical Oncology
160
2
53
0
Get access via publisher
Add to collection
Cite
Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma
Ongerboer de Visser
1
,
Somers
2
,
Nooyen
3
et al.
1983
Neurology
Abstract
Show
124
0
41
0
Get access via publisher
Add to collection
Cite
1
2
3
4
5
6